



## CLL Live 2018 Videos Posted

Videos of the CLL Live 2018 speakers and panels are now posted on [CLLPAG.ca](http://CLLPAG.ca). There are also links to the conference summary and program, speaker bios and the results of the participant evaluation.

---

## IGHV Testing Now Available in Canada - Update

IGHV testing is now available to patients across Canada. IGHV is a “*powerful predictor of duration of response and overall survival with chemo immunotherapy (CIT). As this test may influence choice of therapy between CIT and novel agents, it is critical that providers understand how mutational status is determined and the limitations of testing.*” Crombie & Davids <https://doi.org/10.1002/ajh.24808>

IGHV or mutational status testing is available to all patients through funding provided by Janssen Pharmaceuticals. Physicians can arrange the testing through their Janssen hematology representative. The testing will be done at the Montreal Jewish General Hospital.

TP53 testing was recently recommended for interim funding to all provinces.

---

## CLLPAG Urges Quebec Minister to Approve Venetoclax

Venetoclax (Venclexta) was recently recommended for interim funding by all provinces (except Quebec) by pCODR - see E-Bulletin #13. In Quebec, the Minister of Health and Social Services decided not to fund Venetoclax. CLLPAG has written to Minister Barrette to urge him to reconsider his decision and ensure that all Canadians have equal access to this important medication.